Kyowa Kirin Co., Ltd.
(Revised) Partial Correction of “Financial Summary Supplementary Materials – Fiscal Year Ending December 2025 -”
In the supplementary materials for consolidated results for the fiscal year ending December 2025, a correction was made to a calculation error in the consolidated cash flow statement regarding acquisition expenditures for tangible fixed assets. Revenue was 496.8 billion yen, core operating income was 103.1 billion yen, and net income was 67.0 billion yen.
Key Figures
- Revenue: 496.8 billion yen (Fiscal Year Ending December 2025)
- Core Operating Income: 103.1 billion yen (Year-over-Year +8%)
- Net Income (Quarterly): 67.0 billion yen (Year-over-Year +12%)
AI要約
Performance Overview
Kyowa Kirin Co., Ltd. issued a correction in the supplementary materials for the financial summary of the fiscal year ending December 2025 due to an error in calculation related to "expenditures for acquisition of tangible fixed assets" in the consolidated cash flow statement. Revenue was 496.8 billion yen, nearly flat year-over-year; core operating income rose 8% year-over-year to 103.1 billion yen; and net income increased 12% to 67.0 billion yen. Research and development expenses were 101.2 billion yen, down 2% year-over-year, with an R&D expense ratio of 20.4%. Capital expenditures amounted to 35.8 billion yen for tangible fixed assets and 48.1 billion yen for intangible assets.
Segment Revenue and Product Trends
In regional revenue breakdown, overseas sales ratio reached 74%, with North America as the largest market recording 211.0 billion yen and EMEA at 78.5 billion yen. Among key products, Crysvita posted sales of 216.4 billion yen, up 9% year-over-year, and Poteligeo increased 20% to 45.7 billion yen. Technology income also showed an upward trend, reaching 48.8 billion yen. The number of employees was 5,161, down 508 compared to the previous year, reflecting progressed efficiency improvements.
